Webinars
CGMP-Compliant iPSC Manufacturing and Development of Differentiated Cells for Advanced Therapies: Strategies and Challenges
In this webinar, experts discuss the current state-of-the-art for iPSC generation and differentiation. The presentation will also highlight the development of advanced CGMP-compatible protocols for converting these cells into several cell types of therapeutic relevance, including retinal pigment epithelium (RPE), mesenchymal stem cells (MSCs), cardiomyocytes (CMs), and immune natural killer (NK) cells.
View Now
Article
The Current State of the Cell Therapy Market: Q&A with Maria Lopez, General Manager, US Cell Therapy at Catalent Biologics
Catalent’s Maria Lopez, General Manager of US Cell Therapy discusses the current state of the cell therapy market and the ways Catalent is working to overcome some of these challenges. Based on an interview conducted by, and published in, BioBuzz.
View Now
Webinars
GMP Process for High-Quality iPSC Manufacturing and Development of Improved Differentiation Methodologies
In this webinar, experts will discuss the evolution of protocols associated with induced pluripotent stem cell generation and differentiation.
View Now
Executive Summary
Early Phase Support for Plasmid DNA Supply to Secure Future Manufacturing
Summary: One significant challenge in the manufacturing of cell and gene therapies is the production of high quality plasmid DNA (pDNA). pDNA is a critical raw material for advanced therapeutics including mRNA and viral vector-based cell and gene therapies and vaccines.
View Now
Video
Catalent’s iPSCs as a Starting Material for Advanced Cell Therapies
Summary: iPSCs are a critical starting material for advanced cell therapies. Learn more about Catalent’s GMP iPSC capabilities including reprogramming, differentiation, and cell banking, and how they can advance cell therapies to clinic.
View Now
Article
White Papers
Advancing Towards a Universal Platform for iPSC-Based Therapies
Human induced pluripotent stem cells (iPSCs) enable availability of next-generation cell therapies for broader patient population at a faster turnaround time for a variety of disease areas. Catalent iPSC expert Boris Greber discusses the use of iPSCs as starting materials for cellular therapies, including the concept behind a universal platform for iPSC-based therapies.
View Now
White Papers
Integrated Solutions for Advanced Therapies
Drug developers face mounting challenges linked to rapid increases in demand for the complex modalities while also accounting for the need to drive process efficiencies at scale. Working with the right partner, that offers integrated services, can help ease the increasingly common problems with scale, access to high-demand raw material, viral vector production, and quality requirements.
View Now
Video
Catalent Cell & Gene Therapies – Changing the Healthcare Landscape
Summary: Catalent Cell & Gene Therapy experts spoke with American Pharmaceutical Review to discuss how cell and gene therapies are changing the healthcare landscape and what needs to be done to bring these advanced therapies to patients.
View Now
Webinars
Strategic Considerations for Scaling Up the Manufacturing of Cell Therapies
Join us as our panel of experts discuss key manufacturing challenges for early and late-stage gene-enabled cell therapy programs, as well as how to overcome them through effective partnerships.
View Now
Webinars
Overcoming Manufacturing Challenges for Gene-Enabled Cell Therapies
Summary: Join us as our panel of experts discuss key manufacturing challenges for early and late-stage gene-enabled cell therapy programs, as well as how to overcome them through effective partnerships.
View Now